TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Sponsor: Enliven Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$691,152

Rescue Site Savings

+$471,240

Unlock Full NCT05304377 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05304377 Rescue Dossier →